Next Article in Journal
Safety of Adjuvant Endocrine Therapies in Hormone Receptor–Positive Early Breast Cancertissues
Previous Article in Journal
The Contemporary Role of Surgery in Kidney Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 16
Issue s1
10.3747/co.v16i0.455
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

An Updated Review on the Efficacy of Adjuvant Endocrine Therapies in Hormone Receptor–Positive Early Breast Cancer

by
S. Verma
1,*,
S. Sehdev
2,
A. Joy
3,
Y. Madarnas
4,
J. Younus
5 and
J. A. Roy
6
1
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
2
The Oncology Group, William Osler Health Centre, Brampton, ON, Canada
3
Cross Cancer Centre, Edmonton, AB, Canada
4
Kingston Regional Cancer Centre, Kingston, ON, Canada
5
London Regional Cancer Center, London, ON
6
L’Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2009, 16(s1), 1-13; https://doi.org/10.3747/co.v16i0.455
Submission received: 2 April 2009 / Revised: 16 May 2009 / Accepted: 11 June 2009 / Published: 1 July 2009

Abstract

The third-generation aromatase inhibitors (AIs) are largely replacing tamoxifen in the adjuvant treatment of early-stage breast cancer in postmenopausal women with hormone receptor–positive tumours. To date, multiple trials have been conducted comparing tamoxifen treatment with an AI, and all have demonstrated improved disease-free survival with AI treatment. Trials have included direct 5-year comparisons between tamoxifen and an AI, switching to an AI within 5 years after initial tamoxifen treatment, or extending treatment with an AI after 5 years of completed tamoxifen treatment. Some of these trials have been completed; others are ongoing; and head-to-head trial comparisons of individual AIs are also in progress. The present article summarizes the data obtained from various clinical trials of hormonal therapy for early breast cancer. It also reviews recent data so as to shed light on the current status of these therapies. The focus is on the efficacy of treatment with an AI. Toxicity is discussed in the second article in this supplement.
Keywords: adjuvant endocrine therapy; hormonal therapy; aromatase inhibitors; early-stage breast cancer adjuvant endocrine therapy; hormonal therapy; aromatase inhibitors; early-stage breast cancer

Share and Cite

MDPI and ACS Style

Verma, S.; Sehdev, S.; Joy, A.; Madarnas, Y.; Younus, J.; Roy, J.A. An Updated Review on the Efficacy of Adjuvant Endocrine Therapies in Hormone Receptor–Positive Early Breast Cancer. Curr. Oncol. 2009, 16, 1-13. https://doi.org/10.3747/co.v16i0.455

AMA Style

Verma S, Sehdev S, Joy A, Madarnas Y, Younus J, Roy JA. An Updated Review on the Efficacy of Adjuvant Endocrine Therapies in Hormone Receptor–Positive Early Breast Cancer. Current Oncology. 2009; 16(s1):1-13. https://doi.org/10.3747/co.v16i0.455

Chicago/Turabian Style

Verma, S., S. Sehdev, A. Joy, Y. Madarnas, J. Younus, and J. A. Roy. 2009. "An Updated Review on the Efficacy of Adjuvant Endocrine Therapies in Hormone Receptor–Positive Early Breast Cancer" Current Oncology 16, no. s1: 1-13. https://doi.org/10.3747/co.v16i0.455

APA Style

Verma, S., Sehdev, S., Joy, A., Madarnas, Y., Younus, J., & Roy, J. A. (2009). An Updated Review on the Efficacy of Adjuvant Endocrine Therapies in Hormone Receptor–Positive Early Breast Cancer. Current Oncology, 16(s1), 1-13. https://doi.org/10.3747/co.v16i0.455

Article Metrics

Back to TopTop